Abstract
It has been clear since the second half of the last decade that a proportion of patients with disseminated malignant lymphoma are curable (1,2,3). Since then strenuous efforts have been made to increase that proportion. Selected examples of the approaches taken to this end, and the results achieved will be presented in this paper.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
DeVita V. Jr., Serpick A, Carbone P: Combination chemo-therapy in the treatment of advanced Hodgkin’s disease. Ann. Int. Med. 73: 881–895, 1979.
Sutcliffe S, Wrigley P, Peto J, et al: MVPP chemtherapy regimen for advanced Hodgkin’s disease. Br Med J 1: 679–683, 1978
DeVita VT, Chabner B, Hubbard SP et al: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1: 248–250, 1975.
Sutcliffe S, Wrigley P, Timothy A, et al: Post-treatment laparotomy as a guide to management in patients with Hodgkin1s disease. Cancer Treat Rep 66 4: 759–765, 1982.
Santoro A, Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodgkin1s disease after treatment with adriamycin, bleomycin, vinblastine and decarbazine (ABVD). Cancer Chemother Pharmacol 2: 101–105, 1979.
Santoro A, Bonadonna G, Bonfante V, et al: Alternating drug combinations in the treatment of advanced Hodgkinfs disease. N Engl J Med 306: 770–775, 1982.
Canellos G, Come S, Skarin A: Chemotherapy in the treatment of Hodgkinfs disease. Semin Haemat 20: 1–23, 1983.
Skarin A, Canellos G, Rosenthal D, et al: Improved Prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1: 91–98, 1983.
Fisher R, DeVita V, Hubbard S, et al: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Int Med 98: 304–309, 1983.
Appelbaum F, Thomas D: Review of the use of marrow transplantation in the treatment of Non-Hodgkin’s lymphoma. J. Clin Oncol 1: 440–447, 1983.
Portlock C, Rosenberg S, Glatstein E et al: Treatment of advanced Non-Hodgkin’s lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47: 747–756, 1976.
Lister TA, Cuilen MH, Beard MEJ et al:Comparison of combined and single agent chemotherapy in Non Hodgkin’s lymphoma of favourable histological type. Br Med J 1: 533–537, 1978.
Ezdinli EZ, Costello WG, Silverstein MN, et al: Moderate versus intensive chemotherapy of prognostically favorable Non-Hodgkin’s iympnoma. Cancer 46: 29–33, 1980.
Kennedy BJ, Bloomfield CD, Kiang DT et al: Combination versus successive single agent chemotherapy in lympho-cytic lymphoma. Cancer 41: 23–28, 1978.
Bell R, Gallagher CJ, Ford J, Malpas JS, Lister TA: Phase II study of a high dose regimen of cyclophosphamide and prednisolone in advanced Non-Hodgkin1s lymphoma of favorable histologic type. Cancer Treat Rep 66: 377–380, 1982.
Portlock CS, Rosenberg SA: No initial therapy for stage III and IV Non-Hodgkin1s lymphomas of favorable histologic type. Ann Int Med 90: 10–13, 1979.
Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and maligant lymphoma. Ann Int Med 93: 399–406, 1980.
Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan RC: Follow up observations on the effect of human leukocyte interferon in Non-Hodgkin’s lymphoma. Blood 58: 712, 1981.
Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517–522, 1982.
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Lister, T.A., Dhaliwal, H.S. (1984). Treatment of Disseminated Malignant Lymphoma. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive